Evolutionary Genomics, Inc.
FNAM · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.03 | -0.02 | 0.35 |
| FCF Yield | -14.26% | -38.45% | -35.51% | -7.09% |
| EV / EBITDA | -8.39 | -4.36 | -3.44 | -11.96 |
| Quality | ||||
| ROIC | -92.59% | -98.79% | -45.78% | -18.35% |
| Gross Margin | 0.00% | 0.00% | -14,245.16% | -67.77% |
| Cash Conversion Ratio | 0.33 | 0.57 | 1.34 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -52.25% | 496,795.43% |
| Free Cash Flow Growth | 59.51% | 31.09% | -267.00% | 16.41% |
| Safety | ||||
| Net Debt / EBITDA | -3.47 | -2.01 | -0.82 | 0.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -4.94 |
| Cash Conversion Cycle | -63.69 | -6.63 | -644.09 | -88.00 |